Search Results

Bionomics Limited announced it has entered into a securities purchase agreement with an institutional accredited investor to purchase American Depository Shares and accompanying warrants in a three-tranche private placement.

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce a proposed non-brokered private placement of up to 10,000,000 units (the “Units”) at a price of $0.10 per Unit for gross proceeds of up to $1,000,000 (the “Offering”).

Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), wishes to announce that

Facing declining valuations and funding challenges, public biotechs like bluebird bio are going private to restructure, reduce regulatory burdens and refocus on long-term growth.

Alis Biosciences’ plan is a familiar tactic in the private equity world, but the firm will instead be listed on the public markets “in due course.”

Precision BioSciences, Inc. today announced that it has entered into a definitive subscription agreement, pursuant to which the Company will issue and sell in a non-brokered private placement to members of its senior leadership team.